PNC Financial Services Group Inc. Acquires 159 Shares of Ascendis Pharma A/S (NASDAQ:ASND)

PNC Financial Services Group Inc. grew its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 1.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,384 shares of the biotechnology company’s stock after acquiring an additional 159 shares during the period. PNC Financial Services Group Inc.’s holdings in Ascendis Pharma A/S were worth $2,064,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC bought a new position in Ascendis Pharma A/S in the fourth quarter worth approximately $25,000. Quadrant Capital Group LLC raised its position in shares of Ascendis Pharma A/S by 90.4% during the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares during the period. Barometer Capital Management Inc. bought a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at $126,000. Finally, Legato Capital Management LLC bought a new stake in shares of Ascendis Pharma A/S during the 4th quarter valued at $204,000.

Ascendis Pharma A/S Stock Down 1.3 %

Ascendis Pharma A/S stock opened at $121.62 on Friday. The company’s 50-day moving average price is $133.53 and its 200-day moving average price is $136.48. Ascendis Pharma A/S has a twelve month low of $85.08 and a twelve month high of $161.00. The company has a market cap of $7.08 billion, a PE ratio of -12.66 and a beta of 0.59.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Thursday, May 2nd. The biotechnology company reported ($2.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.57) by ($0.91). Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 152.68%. The business had revenue of $103.11 million during the quarter, compared to the consensus estimate of $85.72 million. As a group, sell-side analysts expect that Ascendis Pharma A/S will post -5.13 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on ASND shares. StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Thursday, May 23rd. Cantor Fitzgerald restated an “overweight” rating and set a $173.00 price objective on shares of Ascendis Pharma A/S in a research report on Wednesday, May 15th. Stifel Nicolaus began coverage on shares of Ascendis Pharma A/S in a research report on Friday, May 31st. They set a “buy” rating and a $200.00 price objective on the stock. Wells Fargo & Company raised their target price on shares of Ascendis Pharma A/S from $260.00 to $262.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Finally, JPMorgan Chase & Co. lifted their price target on shares of Ascendis Pharma A/S from $167.00 to $170.00 and gave the company an “overweight” rating in a report on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $179.44.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.